- Home
- SNTI vs BOF Comparison
SNTI vs BOF Comparison
Compare SNTI & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- BOF
- Stock Information
- Founded
- SNTI 2016
- BOF 2017
- Country
- SNTI United States
- BOF United States
- Employees
- SNTI N/A
- BOF N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- BOF Packaged Foods
- Sector
- SNTI Health Care
- BOF Consumer Staples
- Exchange
- SNTI Nasdaq
- BOF Nasdaq
- Market Cap
- SNTI 17.8M
- BOF 16.7M
- IPO Year
- SNTI N/A
- BOF 2023
- Fundamental
- Price
- SNTI $3.20
- BOF $2.17
- Analyst Decision
- SNTI Strong Buy
- BOF
- Analyst Count
- SNTI 1
- BOF 0
- Target Price
- SNTI $12.00
- BOF N/A
- AVG Volume (30 Days)
- SNTI 27.8K
- BOF 182.9K
- Earning Date
- SNTI 05-08-2025
- BOF 05-13-2025
- Dividend Yield
- SNTI N/A
- BOF N/A
- EPS Growth
- SNTI N/A
- BOF N/A
- EPS
- SNTI N/A
- BOF N/A
- Revenue
- SNTI N/A
- BOF $6,489,951.00
- Revenue This Year
- SNTI N/A
- BOF N/A
- Revenue Next Year
- SNTI N/A
- BOF N/A
- P/E Ratio
- SNTI N/A
- BOF N/A
- Revenue Growth
- SNTI N/A
- BOF 372.36
- 52 Week Low
- SNTI $1.52
- BOF $0.61
- 52 Week High
- SNTI $16.94
- BOF $4.11
- Technical
- Relative Strength Index (RSI)
- SNTI 44.14
- BOF 50.82
- Support Level
- SNTI $3.33
- BOF $1.80
- Resistance Level
- SNTI $3.63
- BOF $2.82
- Average True Range (ATR)
- SNTI 0.33
- BOF 0.21
- MACD
- SNTI 0.01
- BOF 0.04
- Stochastic Oscillator
- SNTI 25.36
- BOF 36.27
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About BOF BranchOut Food Inc.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are primarily located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.